title: Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis.
abstract: OBJECTIVE
  To report a case of juxtafoveal choroidal neovascularization in a patient with candida chorioretinitis successfully treated with intravitreal bevacizumab.
  
  
  METHODS
  Case report.
  
  
  RESULTS
  A 45-year-old woman previously treated for candida chorioretinitis was presented with reduced vision in the left eye. The patient was investigated with ophthalmoscopy, fluorescein angiography, and optical coherence tomography (OCT). Following initial treatment, fundus examination, fluorescein angiography, and OCT of the right eye revealed a secondary juxtafoveal classic choroidal neovascularization. Following a single intravitreal injection of bevacizumab, the patient had excellent visual recovery, with absence of subretinal or intraretinal fluid in the OCT.
  
  
  CONCLUSIONS
  Bevacizumab was effective in treatment of choroidal neovascularization associated with candida chorioretinitis.
authors.affiliation: Bristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Lower Maudlin Street, Bristol, BS1 2LX, UK.
authors.forename: Georgios
authors.initials: G
authors.lastname: Makragiannis
authors.affiliation: Bristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Lower Maudlin Street, Bristol, BS1 2LX, UK.
authors.forename: Kaveh
authors.initials: K
authors.lastname: Vahdani
authors.affiliation: Bristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Lower Maudlin Street, Bristol, BS1 2LX, UK. carregnito@gmail.com.
authors.forename: Ester
authors.identifier: http://orcid.org/0000-0002-0055-9547
authors.initials: E
authors.lastname: Carreño
authors.affiliation: Bristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Lower Maudlin Street, Bristol, BS1 2LX, UK.|School of Clinical Sciences, Faculty of Medicine and Dentistry, University of Bristol, Bristol, UK.|National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK.
authors.forename: Richard W J
authors.initials: RWJ
authors.lastname: Lee
authors.affiliation: Bristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Lower Maudlin Street, Bristol, BS1 2LX, UK.|School of Clinical Sciences, Faculty of Medicine and Dentistry, University of Bristol, Bristol, UK.|National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK.
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Dick
authors.affiliation: Bristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Lower Maudlin Street, Bristol, BS1 2LX, UK.
authors.forename: Adam H
authors.initials: AH
authors.lastname: Ross
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D002177:Candidiasis / Q000150:complications*; D002825:Chorioretinitis / Q000209:etiology*; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D015821:Eye Infections, Fungal / Q000150:complications*; D005260:Female; D006801:Humans; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab
keywords: Bevacizumab; Candida; Chorioretinitis; Choroidal neovascular membrane